344 related articles for article (PubMed ID: 33194055)
1. Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma.
Hu Y; Hao M; Chen Q; Chen Z; Lin H
Am J Transl Res; 2020; 12(10):6584-6598. PubMed ID: 33194055
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
3. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
6. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
7. Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study.
Ouyang T; Liu J; Shi C; Zhu L; Guo X
J Hepatocell Carcinoma; 2021; 8():1459-1471. PubMed ID: 34858890
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
9. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
10. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
Zhang H; Wu C; Chen M; Sun Y; Han J
J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
[TBL] [Abstract][Full Text] [Related]
13. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy and safety of conventional transarterial chemoembolization and drug-eluting bead transarterial chemoembolization in unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective cohort study.
Zhang Z; Jiang N; Yin X; Xu A; Hao Y; Li H; Yang W; Mu K
Eur J Radiol; 2024 Jun; 176():111541. PubMed ID: 38843693
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
[TBL] [Abstract][Full Text] [Related]
17. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
18. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
Zhao C; Ma SPZCY
J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]